Volume in Focus: Prana Biotechnology Limited, Petroleo Brasileiro Petrobras, Cytori Therapeutics, Peregrine Pharmaceuticals

Dallas, TX -- (SBWIRE) -- 03/06/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares gained 16.85% to $2.67 in the morning hour after the company today announced that PBT434, Prana's lead drug candidate for Parkinson's Disease (PD) and movement disorders, will be presented at two international conferences in March. The key finding to be reported is that PBT434 reduces the aggregation and accumulation of a key protein (alpha-synuclein) in multiple transgenic animal models of the disease.

Is PRAN a Strong Buy After The Recent Gain? Let’s Find out Here

Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) shares jumped 12.70% to $16.33. PBR’s stock, on Mar. 1, has been reiterated by TheStreet Ratings as a hold with a ratings score of C. The company's strengths can be seen in multiple areas, such as its increase in net income, attractive valuation levels and growth in earnings per share.

Additionally, the company yesterday informs the increase of 5% in diesel price at the refinery gate, with effect from March 6th, 2013. The price of diesel which the readjustment applies to does not include federal taxes (CIDE, PIS/Cofins) and state taxes (ICMS). This price readjustment was calculated by the Company taking into account the Company's pricing policy, which seeks to align the price of oil products with the international market in the medium and long-term.

Is PBR a Strong Buying Opportunity After The Recent Slump? Find out Here

Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) stock jumped 7.44% to $2.89. The company will provide a live webcast of its fourth quarter and year end financial results and business update on Thursday, March 7, 2013 at 5:00 PM Eastern Time. Prior to the webcast at approximately 4:05 PM Eastern Time on March 7, Cytori will issue its year end earnings release which will review Cytori's fourth quarter and full year performance.

Should Investors Consider CYTX After The Recent price Action? Get Free Trend Analysis Here

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares gained 6.79% to $1.39. The company announced that it will report financial results for the third quarter of the fiscal year (FY) 2013 on March 12, 2013 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the third quarter ended January 31, 2013 of FY 2013 and will review recent progress of its clinical development programs.

Additionally, analysts at Piper Jaffray assumed coverage on shares of PPHM in a note issued to investors on Mar. 5. The firm set an “overweight” rating and a $2.50 price target on the stock.

Should Investors Consider PPHM After The Recent price Action? Get Free Trend Analysis Here

About Marketbuzzreport.com
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com

Disclaimer
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.